SCHEMBL24878736

SCHEMBL24878736

CC(=O)NC1CCN(C(=O)c2nn(CC(=O)N3CCN(c4cccc(C(F)(F)F)c4C)CC3)c3c2[C@@H]2C[C@@H]2C3)CC1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.66
ALOX15 P16050 2/20 0.36
RAB9A P51151 2/20 0.36
CCR1 P32246 6/20 0.35
NPC1 O15118 1/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CXCR3 P49682 1/20 0.34
KCNH2 Q12809 1/20 0.34
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CFD P00746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30129500 0.91 IDO1 (0.75) IDO1ALOX15RAB9ANPC1KDM4E
SCHEMBL24878590 0.91 IDO1 (0.75) IDO1ALOX15RAB9ANPC1KDM4E
SCHEMBL21996022 0.90 IDO1 (0.69) IDO1ALOX15RAB9ACCR1NPC1
SCHEMBL31011190 0.90 IDO1 (0.69) IDO1ALOX15RAB9ACCR1NPC1
SCHEMBL30129082 0.89 IDO1 (0.64) IDO1ALOX15RAB9ACCR1NPC1
SCHEMBL21995905 0.89 IDO1 (0.64) IDO1ALOX15RAB9ACCR1NPC1
SCHEMBL21995924 0.87 IDO1 (0.60) IDO1ALOX15RAB9ACCR1NPC1
SCHEMBL30128966 0.87 IDO1 (0.60) IDO1ALOX15RAB9ACCR1NPC1
SCHEMBL24878343 0.86 IDO1 (0.61) IDO1ALOX15RAB9ACCR1NPC1
SCHEMBL24878733 0.86 IDO1 (0.85) IDO1ALOX15RAB9ACCR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886845-B1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-09-04 EP claimed
US-12264134-B2 Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2025-04-01 US disclosed
US-20230008022-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2023-01-12 US disclosed
US-20230008022-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008022-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU IDO1 1/4885ALOX15 633/4885RAB9A 2933/4885
US-12264134-B2 Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, AADAC IDO1 1/4885ALOX15 859/4885RAB9A 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.